The site is undergoing maintenance on
Thursday, September 10, 9:30 pm through Friday, September 11, 5:30 am (IST), 2026.
If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
See More
The site is undergoing maintenance on
Thursday, September 10, 9:30 pm through Friday, September 11, 5:30 am (IST), 2026.
If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
See MoreThe site is undergoing maintenance on
Thursday, September 10, 9:30 pm through Friday, September 11, 5:30 am (IST), 2026
.If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Two-color flow cytometric analysis of Ly-6C expression on mouse splenocytes. Splenic leucocytes from a BALB/c mouse were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were then stained with FITC Rat Anti-Mouse CD8a antibody (Cat. No. 553031/553030/561966) and with either BD Horizon™ BV605 Rat IgM, κ Isotype Control (Cat. No. 563062, Left Panel) or with BD Horizon™ BV605 Rat Anti-Mouse Ly-6C antibody (Cat. No. 563011, Right Panel). Two-color flow cytometric dot plots showing the correlated expression of Ly-6C (or Ig isotype control staining) versus CD8a were derived from gated events with the forward and side light-scattering characteristics of viable splenocytes. Flow cytometry was performed with a BD™ LSR II Flow Cytometry System.
Two-color flow cytometric analysis of Ly-6C expression on mouse splenocytes. Splenic leucocytes from a BALB/c mouse were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were then stained with FITC Rat Anti-Mouse CD8a antibody (Cat. No. 553031/553030/561966) and with either BD Horizon™ BV605 Rat IgM, κ Isotype Control (Cat. No. 563062, Left Panel) or with BD Horizon™ BV605 Rat Anti-Mouse Ly-6C antibody (Cat. No. 563011, Right Panel). Two-color flow cytometric dot plots showing the correlated expression of Ly-6C (or Ig isotype control staining) versus CD8a were derived from gated events with the forward and side light-scattering characteristics of viable splenocytes. Flow cytometry was performed with a BD™ LSR II Flow Cytometry System.
Two-color flow cytometric analysis of Ly-6C expression on mouse splenocytes. Splenic leucocytes from a BALB/c mouse were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were then stained with FITC Rat Anti-Mouse CD8a antibody (Cat. No. 553031/553030/561966) and with either BD Horizon™ BV605 Rat IgM, κ Isotype Control (Cat. No. 563062, Left Panel) or with BD Horizon™ BV605 Rat Anti-Mouse Ly-6C antibody (Cat. No. 563011, Right Panel). Two-color flow cytometric dot plots showing the correlated expression of Ly-6C (or Ig isotype control staining) versus CD8a were derived from gated events with the forward and side light-scattering characteristics of viable splenocytes. Flow cytometry was performed with a BD™ LSR II Flow Cytometry System.
Two-color flow cytometric analysis of Ly-6C expression on mouse splenocytes. Splenic leucocytes from a BALB/c mouse were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were then stained with FITC Rat Anti-Mouse CD8a antibody (Cat. No. 553031/553030/561966) and with either BD Horizon™ BV605 Rat IgM, κ Isotype Control (Cat. No. 563062, Left Panel) or with BD Horizon™ BV605 Rat Anti-Mouse Ly-6C antibody (Cat. No. 563011, Right Panel). Two-color flow cytometric dot plots showing the correlated expression of Ly-6C (or Ig isotype control staining) versus CD8a were derived from gated events with the forward and side light-scattering characteristics of viable splenocytes. Flow cytometry was performed with a BD™ LSR II Flow Cytometry System.
Two-color flow cytometric analysis of Ly-6C expression on mouse splenocytes. Splenic leucocytes from a BALB/c mouse were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were then stained with FITC Rat Anti-Mouse CD8a antibody (Cat. No. 553031/553030/561966) and with either BD Horizon™ BV605 Rat IgM, κ Isotype Control (Cat. No. 563062, Left Panel) or with BD Horizon™ BV605 Rat Anti-Mouse Ly-6C antibody (Cat. No. 563011, Right Panel). Two-color flow cytometric dot plots showing the correlated expression of Ly-6C (or Ig isotype control staining) versus CD8a were derived from gated events with the forward and side light-scattering characteristics of viable splenocytes. Flow cytometry was performed with a BD™ LSR II Flow Cytometry System.
Two-color flow cytometric analysis of Ly-6C expression on mouse splenocytes. Splenic leucocytes from a BALB/c mouse were preincubated with Purified Rat Anti-Mouse CD16/CD32 antibody (Mouse BD Fc Block™) (Cat. No. 553141/553142). The cells were then stained with FITC Rat Anti-Mouse CD8a antibody (Cat. No. 553031/553030/561966) and with either BD Horizon™ BV605 Rat IgM, κ Isotype Control (Cat. No. 563062, Left Panel) or with BD Horizon™ BV605 Rat Anti-Mouse Ly-6C antibody (Cat. No. 563011, Right Panel). Two-color flow cytometric dot plots showing the correlated expression of Ly-6C (or Ig isotype control staining) versus CD8a were derived from gated events with the forward and side light-scattering characteristics of viable splenocytes. Flow cytometry was performed with a BD™ LSR II Flow Cytometry System.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
The AL-21 monoclonal antibody specifically binds to a non-polymorphic determinant of Ly-6C, a 14-17 kDa GPI-linked cell-surface antigen found on some monocyte/macrophage populations, granulocytes, endothelial cells, plasma cells, and thymocyte, NK-cell, and T-subsets. Mice with the Ly-6.2 alloantigen (eg, AKR, C57BL, C57BR, C57L, C58, DBA/2, PL, SJL, SWR, 129) have subsets of CD8+ and CD4+ Ly-6C+ T cells, while Ly-6.1 strains (eg, A, BALB/c, CBA, C3H/He, DBA/1, NZB) have only CD8+ Ly-6C+ T cells. Upregulation of Ly-6C expression on CD8+ T cells by interferons α and β and poly (I:C) has been described, and Ly-6C is a memory marker on CD8+ T cells.
This antibody is conjugated to BD Horizon BV605 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max of 602-nm, BD Horizon BV605 can be excited by a violet laser and detected with a standard 610/20-nm filter set. BD Horizon BV605 is a tandem fluorochrome of BD Horizon BV421 and an acceptor dye with an Em max at 605-nm. Due to the excitation of the acceptor dye by the green (532 nm) and yellow-green (561 nm) lasers, there will be significant spillover into the PE and BD Horizon PE-CF594 detectors off the green or yellow-green lasers. BD Horizon BV605 conjugates are very bright, often exhibiting brightness equivalent to PE conjugates and can be used as a third color off of the violet laser.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.